Zhenghai Biotech (300653): The year-on-year decline in performance has narrowed, and is optimistic about the restoration of fundamentals
Zhenghai Biotech (300653): The year-on-year decline in 2Q performance narrowed and is optimistic about subsequent recovery
Zhenghai Biotech (300653): 1Q consumer medical demand still hasn't recovered, waiting for flowers to blossom
Zhenghai Biology (300653): Short-term performance, active biological bone under pressure will soon be released
Zhenghai Biotech (300653): Performance is in line with expectations, core products maintain market leadership
Zhenghai Biotech (300653) Annual Results Review: Stable fundamentals, optimistic about commercialization progress of active bone in 24 years
Zhenghai Biotech (300653): Gross margin increased year-on-year, increased R&D investment
Zhenghai Biology (300653): Short-term performance is under pressure and commercialization of active bone can be expected in 24 years
Zhenghai Biotech (300653): Short-term performance is under pressure, waiting for flowers to blossom
Zhenghai Biology (300653): China's leading regenerative medicine material, active biomedical bone is expected to accelerate performance growth
Review of the 2023 Semi-Annual Report of Zhenghai Biotech (300653): Short-term performance is under pressure and optimistic that growth will resume throughout the year
Zhenghai Biotech (300653): Gross margin for the second quarter alone increased month-on-year, further improving internal quality and efficiency
Zhenghai Biotech (300653): Marginal revenue improvement, profit margin rising steadily
Zhenghai Biotech (300653): Performance on repair track, optimistic about continued product release
Zhenghai Biology (300653): Gathering opens up 100 billion potential space for dental implants, leading quantities of regenerative medicine materials are about to be released
Zhenghai Biotech (300653): The impact of the epidemic on short-term performance is under pressure, and we are optimistic about the full year's restorative growth
Zhenghai Biotech (300653): The growth rate of 1Q performance is under pressure and is optimistic about the resumption of medical treatment throughout the year
Zhenghai Biotech (300653) 2022 Review: The main business is stabilizing, improving, and innovative products are being launched one after another
Zhenghai Biotech (300653): Oral membrane business is growing steadily, product innovation and sales expansion help sustainable development
Zhenghai Biotech (300653): Steady performance under the influence of the epidemic in 2022 and optimistic that the growth rate will pick up in 2023